Low fixed dose rasburicase for tumour lysis syndrome prophylaxis and treatment is feasible and efficacious in the management of haematologic malignancies
{{output}}
IntroductionRasburicase is a high-cost medicine indicated for the prevention and treatment of tumour lysis syndrome (TLS). Growing evidence supports low fixed-dose rasburicase regimens (3-6 mg), however, uncertainty remains regarding their ability to prevent p... ...
